Retinoid pharmacology

Therapy of Skin Diseases: A Worldwide Perspective on Therapeutic Approaches and Their Molecular Basis

Volumn , Issue , 2010, Pages 77-85

  Baron, Jens M ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892116993     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-78814-0_8     Document Type: Chapter

References (58)

1. Kurlandsky SB, Duell EA, Kang S, Voorhees JJ, Fisher GJ (1996) Auto-regulation of retinoic acid biosynthesis through regulation of retinol esterification in human keratinocytes. J Biol Chem 271(26):15346-15352 (Pubitemid 26225301)
2. Petkovich PM (2001) Retinoic acid metabolism. J Am Acad Dermatol 45(5):S136-S142 (Pubitemid 33032592)
3. Roos TC, Jugert FK, Merk HF, Bickers DR (1998) Retinoid metabolism in the skin. Pharmacol Rev 50(2):315-333 (Pubitemid 28304031)
4. Baron JM, Heise R, Blaner W, Neis M, Joussen S, Dreuw A, Marquardt Y, Saurat JH, Merk HF, Bickers DR, Jugert FK (2005) Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol 125(1):143-153 (Pubitemid 40981435)
5. Duell EA, Astrom A, Griffiths CE, Chambon P, Voorhees JJ (1992) Human skin levels of retinoic acid and cytochrome P-450-derived 4-hydroxyretinoic acid after topical application of retinoic acid in vivo compared to concentrations required to stimulate retinoic acid receptor-mediated transcription in vitro. J Clin Invest 90(4):1269-1274
6. Heise R, Mey J, Neis M, Marquardt Y, Joussen S, Ott H, Wiederholt T, Kurschat P, Megahed M, Bickers DR, Merk HF, Baron JM (2006) Skin retinoid concentrations are modulated by CYP26AI expression restricted to basal keratino-cytes in normal human skin and differentiated 3D-skin models. J Invest Dermatol 126:2473-2480 (Pubitemid 44582269)
7. Smith G, Wolf CR, Deeni YY, Dawe RS, Evans AT, Comrie MM, Ferguson J, Ibbotson SH (2003) Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet 361:1336-1343 (Pubitemid 36514866)
8. van de Kerkhof PC (2006) Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatol Ther 19(5):252-263 (Pubitemid 44470109)
9. Karlsson T, Rollman O, Vahlquist A, Torma H (2004) Immunofluorescence localization of nuclear retinoid receptors in psoriasis versus normal human skin. Acta Derm Venereol 84(5):363-369 (Pubitemid 39312269)
10. Fisher GJ, Voorhees JJ (1996) Molecular mechanisms of retinoid actions in skin. FASEB J 10(9):1002-1013 (Pubitemid 26285976)
11. Saurat JH, Didierjean L, Masgrau E, Piletta PA, Jaconi S, Chatellard-Gruaz D, Gumowski D, Masouye I, Salomon D, Siegenthaler G (1994) Topical retinaldehyde on human skin: biologic effects and tolerance. J Invest Dermatol 103(6): 770-774
12. Sorg O, Tran C, Saurat JH (2001) Cutaneous vitamins A and E in the context of ultraviolet-or chemically-induced oxidative stress. Skin Pharmacol Appl Skin Physiol 14(6):363-372 (Pubitemid 34701808)
13. Sorg O, Antille C, Kaya G, Saurat JH (2006) Retinoids in cosmeceuticals. Dermatol Ther 9(5):289-296 (Pubitemid 44470113)
14. Antille C, Tran C, Sorg O, Carraux P, Didierjean L, Saurat JH (2003) Vitamin A exerts a photoprotective action in skin by absorbing ultraviolet B radiation. J Invest Dermatol 121(5): 1163-1167 (Pubitemid 37430988)
15. Creidi P, Vienne MP, Ochonisky S, Lauze C, Turlier V, Lagarde JM, Dupuy P (1998) Profilometric evaluation of photodamage after topical retinaldehyde and retinoic acid treatment. J Am Acad Dermatol 39(6):960-965 (Pubitemid 28547729)
16. Ortonne JP (2006) Retinoid therapy of pigmentary disorders. Dermatol Ther 19(5):280-288
17. Vahlquist A, Lee JB, Michaelsson G, Rollman O (1982) Vitamin A in human skin: II Concentrations of carotene, retinol and dehydroretinol in various components of normal skin. J Invest Dermatol 79(2):94-97 (Pubitemid 12099519)
18. Stuettgen D (1962) Zur Lokalbehandlung von Keratosen mit Vitamin A-Säure. Dermatologica 124:65-80
19. Thielitz A, Krautheim A, Gollnick H (2006) Update in retin-oid therapy of acne. Dermatol Ther 19(5):272-279
20. Krautheim A, Gollnick HP (2004) Acne: topical treatment. Clin Dermatol 22(5):398-407 (Pubitemid 39535282)
21. Bianchi L, Orlandi A, Campione E, Angeloni C, Costanzo A, Spagnoli LG, Chimenti S (2004) Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol 151(1): 148-156 (Pubitemid 39061292)
22. Rafal ES, Griffiths CE, Ditre CM, Finkel LJ, Hamilton TA, Ellis CN, Voorhees JJ (1992) Topical tretinoin (retinoic acid) treatment for liver spots associated with photodamage. N Engl J Med 326(6):368-374
23. Uno H, Cappas A, Dong S, Kligman AM (1991) The effect of topical tretinoin on the facial macula of the macaque. J Invest Dermatol 96:632
24. Yoshimura K, Tsukamoto K, Okazaki M, Virador VM, Lei TC, Suzuki Y, Uchida G, Kitano Y, Harii K (2001) Effects of all-trans retinoic acid on melanogenesis in pigmented skin equivalents and monolayer culture of melanocytes. J Dermatol Sci 27(suppl 1):S68-S75
25. Kasraee B, Fallahi MR, Ardekani GS, Ebrahimi S, Doroudchi G, Omrani GR, Handjani F, Amini M, Tanideh N, Haddadi M, Nikbakhsh M, Jahanbani S, Tran C, Sorg O, Saurat JH (2006) Retinoic acid synergistically enhances the melanocy-totoxic and depigmenting effects of monobenzylether of hydroquinone in black guinea pig skin. Exp Dermatol 15(7): 509-514 (Pubitemid 43834485)
26. Kaymak Y, Ilter N (2006) The effectiveness of intermittent isotretinoin treatment in mild or moderate acne. J Eur Acad Dermatol Venereol 20(10):1256-1260 (Pubitemid 44614625)
27. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Summary information on a referral opinion following an arbitration pursuant to article 29 of Directive 2001/83/EC for isotretinoin. CPMP/8211/03, 17 October 2003
28. Baumann L, Vujevich J, Halem M, Martin LK, Kerdel F, Lazarus M, Pacheco H, Black L, Bryde J (2005) Open-label pilot study of alitretinoin gel 0.1% in the treatment of pho-toaging. Cutis 76(1):69-73 (Pubitemid 41097504)
29. Scheinfeld N (2006) Schools of pharmacology: retinoid update. J Drugs Dermatol 5(9):921-922
30. Saurat JH (1999) Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol 41(3 Pt 2):S2-S6
31. Pearce DJ, Klinger S, Ziel KK, Murad EJ, Rowell R, Feldman SR (2006) Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis. Arch Dermatol 142(8):1000-1004 (Pubitemid 44268476)
32. Bikowski JB (2005) Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids. J Drugs Dermatol 4(1):41-47
33. Jain S (2004) Topical tretinoin or adapalene in acne vulgaris: an overview. J Dermatolog Treat 15(4):200-207 (Pubitemid 39013671)
34. Shroot B, Michel S, Allec J, Chatelus A, Wagner N (1998) A new concept of drug delivery for acne. Dermatology 196(1): 165-170 (Pubitemid 28116068)
35. Ioannides D, Rigopoulos D, Katsambas A (2002) Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. Br J Dermatol 147(3):523-527 (Pubitemid 35015289)
36. Pariser DM, Thiboutot DM, Clark SD, Jones TM, Liu Y, Graeber M (2005) The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: a randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle. Cutis 76(2): 145-151 (Pubitemid 41290901)
37. Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Arsonnaud S, Kang S; on behalf of the Differin Study Group (2005) Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skin Med 4(3):138-146
38. Altinyazar HC, Koca R, Tekin NS, Esturk E (2005) Adapalene vs. metronidazole gel for the treatment of rosa-cea. Int J Dermatol 44(3):252-255 (Pubitemid 40425677)
39. Nagpal S, Chandraratna RA (2000) Recent developments in receptor-selective retinoids. Curr Pharm Des 6(9):919-913
40. Nagpal S, Thacher SM, Patel S, Friant S, Malhotra M, Shafer J, Krasinski G, Asano AT, Teng M, Duvic M, Chandraratna RA (1996) Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acid recep-tor-specific retinoid: insight into the mechanism of retinoid action in psoriasis. Cell Growth Differ 7(12):1783-1791 (Pubitemid 26415175)
41. Esgleyes-Ribot T, Chandraratna RA, Lew-Kaya DA, Sefton J, Duvic M (1994) Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol 30(4): 581-590 (Pubitemid 24121758)
42. Krueger GG, Drake LA, Elias PM, Lowe NJ, Guzzo C, Weinstein GD, Lew-Kaya DA, Lue JC, Sefton J, Chandraratna RA (1998) The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol 134(1):57-60 (Pubitemid 28087114)
43. Behrens S, Grundmann-Kollmann M, Schiener R, Peter RU (2000) Kerscher MCombination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol 42(3):493-495 (Pubitemid 30470360)
44. Tzaneva S, Honigsmann H, Tanew A, Seeber A (2002) A comparison of psoralen plus ultraviolet A (PUVA) mono-therapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. Br J Dermatol 147(4):748-753 (Pubitemid 35286162)
45. Dummer R, Cozzio A, Meier S, Beyeler M, Laetsch B, Doebbeling U, Urosevic (2006) Standard and experimental therapy in cutaneous T-cell lymphomas. J Cutan Pathol 33(suppl 1):52-57
46. Budgin JB, Richardson SK, Newton SB, Wysocka M, Zaki MH, Benoit B, Rook AH (2005) Biological effects of bex-arotene in cutaneous T-cell lymphoma. Arch Dermatol 141(3):315-321 (Pubitemid 40365447)
47. Smit J V, de Jong EM, van Hooijdonk CA, Otero ME, Boezeman JB, van de Kerkhof PC (2004) Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. J Am Acad Dermatol 51(2): 257-264
48. Duvic M, Martin AG, Kim Y et al (2001) Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 137:581-593 (Pubitemid 32458440)
49. Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R, Ranki A, Schwandt P, Whittaker S (2006) Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 155(2):261-266 (Pubitemid 44050557)
50. Thacher SM, Vasudevan J, Chandraratna RA (2000) Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des 6(1):25-58 (Pubitemid 30395460)
51. Bardazzi F, Bianchi F, Parente G, Guareschi E, Landi C (2005) A pilot study on the use of topical tazarotene to treat squamous cell carcinoma in situ. J Am Acad Dermatol 52(6): 1102-1104 (Pubitemid 40732561)
52. Peris K, Ferrari A, Fargnoli MC, Piccolo D, Chimenti S (2005) Dermoscopic monitoring of tazarotene treatment of superficial basal cell carcinoma. Dermatol Surg 31(2): 217-220 (Pubitemid 40990955)
53. Lucker GP, Verfaille CJ, Heremans AM, Vanhoutte FP, Boegheim JP, Steijlen PP (2005) Topical liarozole in ich-thyosis: a double-blind, left-right comparative study followed by a long-term open maintenance study. Br J Dermatol 152(3):566-569 (Pubitemid 40547135)
54. Nohynek GJ, Meuling WJ, Vaes WH, Lawrence RS, Shapiro S, Schulte S, Steiling W, Bausch J, Gerber E, Sasa H, Nau H (2006) Repeated topical treatment, in contrast to single oral doses, with Vitamin A-containing preparations does not affect plasma concentrations of retinol, retinyl esters or retinoic acids in female subjects of child-bearing age. Toxicol Lett 163(1):65-76 (Pubitemid 43356620)
55. Loureiro KD, Kao KK, Jones KL, Alvarado S, Chavez C, Dick L, Felix R, Johnson D, Chambers CD (2005) Minor malformations characteristic of the retinoic acid embryopa-thy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A 136(2):117-121 (Pubitemid 40967099)
56. Anadolu RY, Sen T, Tarimci N, Birol A, Erdem C (2004) Improved efficacy and tolerability of retinoic acid in acne vulgaris: a new topical formulation with cyclodextrin complex psi. J Eur Acad Dermatol Venereol 18(4): 416-421 (Pubitemid 38967973)
57. Dreno B, Bettoli V, Ochsendorf F, Perez-Lopez M, Mobacken H, Degreef H, Layton A (2006) An expert view on the treatment of acne with systemic antibiotics and/or oral isotretin-oin in the light of the new European recommendations. Eur J Dermatol 16(5):565-571 (Pubitemid 44861833)
58. Saini R, Tutrone WD, Weinberg JM (2005) Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pime-crolimus. Curr Pharm Des 11(2):273-280